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Since the publication of this paper, the authors have noticed an error
on page 3 of their article. The correct sentence is shown below:
‘In the phase III study of nilotinib versus imatinib as ﬁrst-line
treatment for patients with CP CML, patients receiving imatinib
were more likely to experience all-grade peripheral edema,
eyelid edema and periorbital edema (14, 13 and 12%,
respectively) than patients receiving nilotinib 300mg twice
daily (5, 1 and o1%, respectively) or nilotinib 400mg
twice daily (5, 2 and 1%, respectively).’
The authors apologize for any inconvenience caused.
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Since the publication of the above paper, the authors have
noticed an error in Supplementary Tables 1 and 3.
The authors would like to apologise for any inconvenience this
may have caused.
The corrected supplementary tables can be accessed via the
online version of this corrigendum.
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